



WEST VIRGINIA DRUG UTILIZATION REVIEW BOARD MEETING

April 20, 2026



- **Rachele Poissant, PharmD**
Clinical Account Manager
 - **Cory Chambliss**
Operations Director
 - **Scott Donald, PharmD**
Director of Clinical Services
-
-



RDUR Patient Reviews

	Target Intervention	Profiles Reviewed	Letters Sent	Response Rate
Jan	Inappropriate migraine therapy	495	442	10%
Feb	Management of hypertension in diabetic patients	600	766	7%
Mar	Polypsychopharmacy: antidepressant specific	595	635	4%

RDUR Patient Reviews

January 2026: Inappropriate migraine therapy

Drugs included

- Triptans
- Ergotamine
- Dihydroergotamine

Alert message

- According of migraine-specific medications (exceeding the recommended dosage and/or taking an agent for 10 or more days per month) may result in medication overuse headaches (MOH). Please consider the use of preventative medications such as divalproex, beta-blockers or SSRIs.



RDUR Patient Reviews

February 2026: Management of hypertension in diabetic patients

Drugs included

- Angiotensin-Converting Enzyme Inhibitors
- Angiotensin II Receptor Blockers

Alert message

- According to the ACC/AHA High Blood Pressure Clinical Practice Guideline, the hypertension treatment goal for patients with diabetes is a blood pressure of < 130/80 mm Hg. In order to achieve this goal, multiple antihypertensive agents may be required. Adding an angiotensin-converting enzyme inhibitor or an angiotensin II receptor antagonist should be considered if no contraindications are present. These agents have also been shown to delay the progression of nephropathy in diabetic patients with microalbuminuria.



RDUR Patient Reviews

March 2026: Antidepressant specific polypsychopharmacy

Drugs included

- Antipsychotics
- Antidepressants
- Mood Stabilizers
- Benzodiazepines
- Stimulants

Alert message

- The patient is receiving multi-class polypsychopharmacy. Review the patient's medication history for any unintended additional therapy and assess adherence to ensure efficacy. Complex drug regimens increase the risk of adverse effects, drug/drug interactions, and non-adherence which may result in the relapse of the disease state.



RDUR Outcomes Report

	Criteria	PRE Targeted Patients with Hits	POST Targeted Patients with Hits	POST Targeted Patients with Change
July 2025	CYP2D6 Drug Interactions	268	125	53.36%
August 2025	Increased Risk of Renal Impairment	286	116	59.44%
September 2025	SUPPORT ACT Criteria	427	244	45.20%
Total				52.70%



Lock-In Interventions

Month	Reviewed	Warning Letter	Locked In
Oct	75	3	0
Nov	75	1	0
Dec	75	1	1
Jan	75	0	0
Mar	75	3	0
Apr	75	1	0
Totals	225	9	1

2026 First Quarter Newsletter

FDA Approval Spotlight

- Lerochol (lerodalcibep-liga)*
- Imaavy (nipocalimab-aahu)*
- Rhapsido (remibrutinib)*

*may require a prior authorization

Guideline Update

- 2025 Infectious Diseases Society of America (IDSA) Complicated Urinary Tract Infection (UTI) Guidelines





Accelerating
Better Outcomes